1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Dr. Kerr, I presume?
Clark Ellis brings us a rare interview with British researcher Dr. Jonathan Kerr who is now living in Colombia.
Discuss the article on the Forums.

Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation

Discussion in 'Mast Cell Disorders/Mastocytosis' started by nanonug, Oct 30, 2012.

  1. nanonug

    nanonug Senior Member

    Messages:
    1,248
    Likes:
    385
    Virginia, USA
    J Neuroendocrinol. 2008 May;20 Suppl 1:20-5.
    Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation.

    De Filippis D, D'Amico A, Iuvone T.
    Source

    Department of Experimental Pharmacology, University of Naples Federico II, Naples, Italy.
    Abstract

    The present review aims to elucidate the emerging role played by cannabinomimetic compounds in the control of mast cell activation. Mast cells are immune competent cells strategically localised at the sites directly interfacing with the external environment, which, in case of injury, regulate the immune response by the release of a plethora of both pre-formed and newly-synthesised mediators. However, although the main goal of mast cell activation is to initiate the inflammatory reaction, and thus maintain internal homeostasis, the consequences of dysregulated mast cell activation could be to chronically activate the inflammatory response as occurs in arthritis, inflammatory bowel diseases, atherosclerosis and asthma. Therefore, much effort has been made to develop compounds that act to prevent mast cell degranulation. Cannabinomimetic compounds (i.e. agents able to modulate endocannabinoid function) are considered as an emerging class of regulators of mast cell behaviour. We focus on the evidence for a cannabinomimetic control of both acute and chronic inflammatory disease, recognising a common mast cell origin for problems such as dermatitis, inflammatory gastrointestinal syndrome and granuloma formation. Special emphasis is provided for the recent promising results obtained with palmitoylethanolamide in human studies. In the light of evidence suggesting that the control of mast cell activation at an early time during an inflammatory process may account for its resolution, it is reasonable to propose that cannabinomimetic compounds, including palmitoylethanolamide and its congeners, could represent possible candidates for treating several chronic inflammatory diseases.
    PMID: 18426495
    Waverunner likes this.
  2. determined

    determined Senior Member

    Messages:
    295
    Likes:
    58
    USA: Deep South
    I've never used pot, even before I was sick. Does anyone have any input here? If you have used it since you have been sick, has it helped?
  3. nanonug

    nanonug Senior Member

    Messages:
    1,248
    Likes:
    385
    Virginia, USA
    I have recently started Normast (palmitoylethanolamide) which has some cannabinoid properties. It's expensive but you don't end up in jail if caught with it.

See more popular forum discussions.

Share This Page